Company Overview
ETHZilla Corporation functions as a technology enterprise dedicated to building Ethereum-based infrastructure specifically designed for the tokenization of real-world assets. This operational focus involves developing specialized platforms that facilitate the conversion of illiquid, institutional-grade assets into blockchain-based financial instruments utilizing Ethereum Layer 2 technology. The company operates within the Healthcare sector, specifically classified under the Biotechnology industry, which defines its regulatory environment and market categorization despite its technological core. In terms of scale, ETHZilla holds a market capitalization of $68.63M and reported trailing twelve-month revenue of $4.11M, while the employee count is not disclosed in available public records. The combination of a $68.63M market cap and $4.11M in annual revenue indicates a mid-sized market presence that is currently generating revenue but has not yet achieved profitability, positioning the firm in an early-stage development phase within its niche.
Financial Health
The company reported trailing twelve-month revenue of $4.11M alongside a net income of $-224,528,976 and an EBITDA of $-226,656,496, revealing a significant structural gap where operating costs and expenses substantially exceed total revenue. This disparity indicates that the cost structure is heavily weighted toward research, development, or operational expenditures that have not yet been offset by profitable commercialization. Free cash flow stands at $-441,101,376, which signifies that the company is burning cash at a rapid pace and lacks immediate financial flexibility to fund operations without external capital injections. The gross margin is listed at 100.0%, suggesting that the cost of goods sold is negligible or zero relative to revenue, while the operating margin is -5364.6% and the profit margin is 0.0%, reflecting severe operational inefficiencies or massive non-operating expenses that erode all profits. On the balance sheet, cash holdings of $53.31M are dwarfed by total debt of $546.76M, resulting in a debt-to-equity ratio of 122.83, which characterizes the balance sheet as highly leveraged and potentially vulnerable to interest rate fluctuations or a tightening credit environment. The current ratio is 10.07, indicating that the company possesses ample short-term liquid assets to cover its current liabilities, providing a buffer against immediate solvency issues despite the long-term debt burden. Return on Equity is -96.5% and Return on Assets is -27.8%, metrics that reveal that management has not yet generated positive returns on shareholder capital or the asset base, highlighting the challenges inherent in transitioning a biotechnology-focused entity with a blockchain infrastructure mandate to profitability.
Valuation Assessment
Trailing P/E and forward P/E ratios are both marked as N/A due to the absence of positive earnings, a common characteristic for biotechnology firms in pre-revenue or loss-making stages where traditional earnings-based valuation models are inapplicable. Consequently, the market prices the stock based on alternative metrics, such as the price-to-book ratio of 0.13, which indicates that the market values the company at 13 cents for every dollar of its book value, suggesting a significant discount relative to its accounting equity. The price-to-sales ratio is 16.70, and the EV/EBITDA is -2.52, metrics that suggest the market is valuing the firm primarily on its intangible assets, technological platform potential, and future growth prospects rather than current earnings power. Price metrics show a 52-week high of $174.60 and a 52-week low of $2.99, meaning the stock is trading at the extreme lower end of its recent volatility range and is significantly below its peak performance. The beta value is 1.14, which explains that the stock exhibits price volatility that is 14% higher than the broader market, making it sensitive to general market downturns and suitable only for investors with a high risk tolerance.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings growth relative to revenue expansion within the current fiscal period. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which means the firm does not distribute earnings to shareholders but instead retains all capital to fund its expansion, research, and debt obligations. This reinvestment strategy is typical for companies in the biotechnology sector that prioritize long-term product development and infrastructure building over immediate income distribution. The overall growth and income profile is characterized by a lack of current earnings growth and no dividend income, relying entirely on future potential rather than existing cash flows or shareholder returns.